1.84 (-%)
As of Nov 21, 2024
Source:
Immutep is a late-stage biotechnology company developing novel LAG-3 related immunotherapies for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3).
| Country | United States |
| Headquarters | sydney |
| Phone Number | 612 8315 7003 |
| Industry | manufacturing |
| CEO | Marc Voigt |
| Website | www.immutep.com |